Misonix, Inc. (MSON) |
| 26.54 0 (0%) 04-24 15:47 |
| Open: | 25.38 |
| High: | 26.555 |
| Low: | 25.08 |
| Volume: | 157,169 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 26.99 |
| 52w Low: | 11.14 |
Misonix, Inc., operating alongside its subsidiary entities, specializes in the development, manufacturing, and global commercialization of minimally invasive ultrasonic surgical medical devices. These products serve markets within the United States and internationally. Among its offerings is the BoneScalpel, an ultrasonic system enabling precise cutting and shaping of bone during surgical interventions while carefully preserving surrounding soft tissue. Another key innovation is SonaStar, a surgical aspirator designed to emulsify and extract both soft and hard tumors, predominantly utilized in neurological and general surgical settings. The company also provides SonicOne, an ultrasonic cleansing and debridement solution that specifically targets and removes devitalized tissue and fibrin deposits from wounds and burns, ensuring the protection of viable cells. These instruments find application across a range of clinical disciplines, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound management, and maxillofacial procedures. Sales of its products are conducted through a network of sales representatives and authorized distributors. Misonix, Inc. was established in 1959 and maintains its corporate headquarters in Farmingdale, New York.
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Fri, 29 Oct 2021
Misonix merges with Bioventus - Jones Day
Sat, 14 Aug 2021
What date does 's (MSON) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research
Thu, 29 Jul 2021
Latham & Watkins Advises Bioventus in Acquisition of Misonix - Latham & Watkins LLP
Fri, 07 Jun 2019
Misonix receives U.S. FDA clearance for Nexus, its revolutionary integrated ultrasonic surgical platform - Yole Group
Fri, 03 May 2019
Misonix puts up $97m in stock for Solsys Medical - MassDevice
Tue, 07 Mar 2017
Misonix, Inc. Enters into Exclusive Chinese Distribution Agreement for BoneScalpel - PR Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |